Similar to the aforementioned CP process, consistency and minimization of variance in practice are desirable to improve veteran outcomes. As more experience is obtained with the PA process, its role within the VA will be reviewed and evaluated.
Conclusion
The task of addressing the high cost of today’s anticancer therapies is not one that can be addressed with a single initiative. The ASCO Cost of Care Task Force has been focusing on various initiatives that promote evidence-based decision making aimed at addressing the cost of cancer care. 9 Consistent with this approach, the VA PBM division has been working with key stakeholders at the VISN and local levels to develop interventions aimed at optimizing therapeutic outcomes for the veteran.
Author disclosures
The authors report no actual or potential conflicts of interest with regard to this article.
Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the U.S. Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.